JP2022518507A5 - - Google Patents
Info
- Publication number
- JP2022518507A5 JP2022518507A5 JP2021542397A JP2021542397A JP2022518507A5 JP 2022518507 A5 JP2022518507 A5 JP 2022518507A5 JP 2021542397 A JP2021542397 A JP 2021542397A JP 2021542397 A JP2021542397 A JP 2021542397A JP 2022518507 A5 JP2022518507 A5 JP 2022518507A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- treatment
- composition according
- day
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024102181A JP7823117B2 (ja) | 2019-01-25 | 2024-06-25 | 非典型溶血性尿毒症症候群（ａＨＵＳ）の処置のための抗Ｃ５抗体の投薬量及び投与 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962796953P | 2019-01-25 | 2019-01-25 | |
| US62/796,953 | 2019-01-25 | ||
| PCT/US2020/014998 WO2020154626A1 (en) | 2019-01-25 | 2020-01-24 | Dosage and administration of anti-c5 antibodies for treatment of atypical hemolytic uremic syndrome (ahus) |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024102181A Division JP7823117B2 (ja) | 2019-01-25 | 2024-06-25 | 非典型溶血性尿毒症症候群（ａＨＵＳ）の処置のための抗Ｃ５抗体の投薬量及び投与 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022518507A JP2022518507A (ja) | 2022-03-15 |
| JP2022518507A5 true JP2022518507A5 (https=) | 2023-11-27 |
| JP7511566B2 JP7511566B2 (ja) | 2024-07-05 |
Family
ID=69740563
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021542397A Active JP7511566B2 (ja) | 2019-01-25 | 2020-01-24 | 非典型溶血性尿毒症症候群（ａＨＵＳ）の処置のための抗Ｃ５抗体の投薬量及び投与 |
| JP2024102181A Active JP7823117B2 (ja) | 2019-01-25 | 2024-06-25 | 非典型溶血性尿毒症症候群（ａＨＵＳ）の処置のための抗Ｃ５抗体の投薬量及び投与 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024102181A Active JP7823117B2 (ja) | 2019-01-25 | 2024-06-25 | 非典型溶血性尿毒症症候群（ａＨＵＳ）の処置のための抗Ｃ５抗体の投薬量及び投与 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20220235121A1 (https=) |
| EP (1) | EP3914617B1 (https=) |
| JP (2) | JP7511566B2 (https=) |
| KR (2) | KR20210119420A (https=) |
| CN (2) | CN117838856A (https=) |
| AU (3) | AU2020213121A1 (https=) |
| BR (1) | BR112021014472A2 (https=) |
| CA (1) | CA3127797A1 (https=) |
| DK (1) | DK3914617T3 (https=) |
| ES (1) | ES2980453T3 (https=) |
| FI (1) | FI3914617T3 (https=) |
| HU (1) | HUE067202T2 (https=) |
| LT (1) | LT3914617T (https=) |
| MX (1) | MX2021008919A (https=) |
| PL (1) | PL3914617T3 (https=) |
| PT (1) | PT3914617T (https=) |
| SI (1) | SI3914617T1 (https=) |
| WO (1) | WO2020154626A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3024618A1 (en) | 2016-05-27 | 2017-11-30 | Alexion Pharmaceuticals, Inc. | Methods for treatment of refractory generalized myasthenia gravis |
| DK3658184T5 (da) | 2017-07-27 | 2024-08-26 | Alexion Pharma Inc | Højkoncentrerede anti-c5-antistofformuleringer |
| CN118512588A (zh) | 2017-10-26 | 2024-08-20 | 亚力兄制药公司 | 用于治疗阵发性夜间性血红蛋白尿(pnh)和非典型溶血性尿毒症综合征(ahus)的抗c5抗体的剂量和施用 |
| EP3802593B1 (en) | 2018-05-31 | 2024-09-11 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) in pediatric patients |
| EP3802603A1 (en) | 2018-06-04 | 2021-04-14 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment of atypical hemolytic uremic syndrome (ahus) in pediatric patients |
| US12312394B2 (en) | 2018-06-28 | 2025-05-27 | Alexion Pharmaceuticals, Inc. | Methods of producing anti-C5 antibodies |
| EP3873602B1 (en) | 2018-10-30 | 2023-12-06 | Alexion Pharmaceuticals, Inc. | Subcutaneous dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) |
| EP4281472A1 (en) * | 2021-01-22 | 2023-11-29 | Alexion Pharmaceuticals, Inc. | Methods of treating complement mediated thrombotic microangiopathy using an anti-c5 antibody |
| MX2023013148A (es) * | 2021-05-07 | 2023-11-28 | Novartis Ag | Iptacopan para el tratamiento del sindrome uremico hemolitico atipico. |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6074642A (en) | 1994-05-02 | 2000-06-13 | Alexion Pharmaceuticals, Inc. | Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| PY09026846A (es) | 2008-08-05 | 2015-09-01 | Novartis Ag | Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5 |
| WO2014099546A1 (en) | 2012-12-19 | 2014-06-26 | Promerus, Llc | Process for the preparation of high purity norbornene alkanols and derivatives thereof |
| NZ631007A (en) | 2014-03-07 | 2015-10-30 | Alexion Pharma Inc | Anti-c5 antibodies having improved pharmacokinetics |
| BR112017011235A2 (pt) | 2014-12-19 | 2018-02-06 | Chugai Pharmaceutical Co Ltd | anticorpos anti-c5 e métodos de uso |
| EP3402816A1 (en) * | 2016-01-11 | 2018-11-21 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment |
| CN116769024A (zh) | 2016-06-14 | 2023-09-19 | 瑞泽恩制药公司 | 抗c5抗体及其用途 |
| DK3658184T5 (da) * | 2017-07-27 | 2024-08-26 | Alexion Pharma Inc | Højkoncentrerede anti-c5-antistofformuleringer |
| CN118512588A (zh) * | 2017-10-26 | 2024-08-20 | 亚力兄制药公司 | 用于治疗阵发性夜间性血红蛋白尿(pnh)和非典型溶血性尿毒症综合征(ahus)的抗c5抗体的剂量和施用 |
| EP3802603A1 (en) * | 2018-06-04 | 2021-04-14 | Alexion Pharmaceuticals, Inc. | Dosage and administration of anti-c5 antibodies for treatment of atypical hemolytic uremic syndrome (ahus) in pediatric patients |
-
2020
- 2020-01-24 CN CN202410035211.2A patent/CN117838856A/zh active Pending
- 2020-01-24 CA CA3127797A patent/CA3127797A1/en active Pending
- 2020-01-24 PL PL20708762.8T patent/PL3914617T3/pl unknown
- 2020-01-24 EP EP20708762.8A patent/EP3914617B1/en active Active
- 2020-01-24 AU AU2020213121A patent/AU2020213121A1/en not_active Abandoned
- 2020-01-24 JP JP2021542397A patent/JP7511566B2/ja active Active
- 2020-01-24 SI SI202030425T patent/SI3914617T1/sl unknown
- 2020-01-24 WO PCT/US2020/014998 patent/WO2020154626A1/en not_active Ceased
- 2020-01-24 CN CN202080016936.7A patent/CN113614105A/zh active Pending
- 2020-01-24 HU HUE20708762A patent/HUE067202T2/hu unknown
- 2020-01-24 KR KR1020217024820A patent/KR20210119420A/ko not_active Ceased
- 2020-01-24 BR BR112021014472-2A patent/BR112021014472A2/pt unknown
- 2020-01-24 US US17/424,794 patent/US20220235121A1/en not_active Abandoned
- 2020-01-24 LT LTEPPCT/US2020/014998T patent/LT3914617T/lt unknown
- 2020-01-24 KR KR1020257001928A patent/KR20250016490A/ko active Pending
- 2020-01-24 MX MX2021008919A patent/MX2021008919A/es unknown
- 2020-01-24 FI FIEP20708762.8T patent/FI3914617T3/fi active
- 2020-01-24 PT PT207087628T patent/PT3914617T/pt unknown
- 2020-01-24 ES ES20708762T patent/ES2980453T3/es active Active
- 2020-01-24 DK DK20708762.8T patent/DK3914617T3/da active
-
2024
- 2024-06-25 JP JP2024102181A patent/JP7823117B2/ja active Active
- 2024-11-22 AU AU2024266818A patent/AU2024266818B2/en active Active
-
2026
- 2026-02-04 AU AU2026200805A patent/AU2026200805A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022518507A5 (https=) | ||
| FI3914617T3 (fi) | Anti-c5-vasta-aineiden annostus ja antaminen epätyypillisen hemolyyttis-ureemisen oireyhtymän (ahus) hoitoon | |
| RU2013149792A (ru) | Способы лечения состояний, связанных с masp-2 зависимой активацией комплемента | |
| JP2021526534A5 (https=) | ||
| JP2008520669A (ja) | エリスロポエチン抵抗性を治療する方法 | |
| JP2023533030A5 (https=) | ||
| Nakamura et al. | Acute encephalopathy due to aluminum toxicity successfully treated by combined intravenous deferoxamine and hemodialysis | |
| Teixeira et al. | Continuous kidney replacement therapies: core curriculum 2025 | |
| Allan et al. | Frequently relapsing thrombotic thrombocytopenic purpura treated with cytotoxic immunosuppressive therapy | |
| Lippi et al. | Double filtration plasmapheresis in a dog with multiple myeloma and hyperviscosity syndrome | |
| Stepniewska et al. | The activation of complement system in different types of renal replacement therapy | |
| Lamy et al. | Comparison between on-line high-efficiency hemodiafiltration and conventional high-flux hemodialysis for polyclonal free light chain removal | |
| Vaaraa et al. | Renal Replacement Therapy | |
| DK1948205T3 (en) | Process for metabolic control and high solute clearance, as well as solutions for use therein | |
| Caruana et al. | Controlled study of heparin versus epoprostenol sodium (prostacyclin) as the sole anticoagulant for chronic hemodialysis | |
| Bailey et al. | Comparison of intermittent haemodialysis, prolonged intermittent renal replacement therapy and continuous renal replacement haemofiltration for lithium toxicity: a case report | |
| JP2023526590A5 (https=) | ||
| Agreda‐Vásquez et al. | Starch and albumin mixture as replacement fluid in therapeutic plasma exchange is safe and effective | |
| Vos et al. | Drug clearance by continuous haemodiafiltration: results with the AN-69 capillary haemofilter and recommended dose adjustments for seven antibiotics | |
| Ptak et al. | Immunoadsorption therapy and complement activation | |
| Leitman et al. | Homozygous familial hypercholesterolemia. Selective removal of low‐density lipoproteins by secondary membrane filtration | |
| JP2023507852A5 (https=) | ||
| Weisbord et al. | Iodinated contrast media and the role of renal replacement therapy | |
| Miyakawa et al. | Dialysis | |
| US9861685B2 (en) | Methods of treating hemoglobinopathies |